# Neuromuscular Electrical Stimulation to Combat Muscle Atrophy During Spaceflight: A Narrative Review of Mechanisms and Potential Applications

**Authors:** Broderick L. Dickerson, Ryan J. Sowinski, Drew E. Gonzalez

PMC · DOI: 10.3390/life16020258 · Life · 2026-02-03

## TL;DR

This review explores how neuromuscular electrical stimulation could help prevent muscle loss in astronauts during long space missions.

## Contribution

The paper reviews the potential of NMES as a novel countermeasure for muscle atrophy in spaceflight.

## Key findings

- Ground-based studies show NMES promotes muscle growth in diseased or injured populations.
- NMES is proposed as a low-effort exercise modality for astronauts to combat muscle atrophy.
- Current spaceflight countermeasures include resistance and aerobic training devices.

## Abstract

As humanity continues to strive for extraplanetary exploration, which is quickly gaining marked governmental and industrial support and recognition, there are still substantial detriments to astronaut health during long-duration spaceflight (i.e., muscle atrophy) that must be addressed. The effects of long-duration spaceflight on muscle architecture, morphology, and function have been well documented since the Apollo and Space Shuttle Programs. Countermeasures focused on resistance or aerobic training, such as the Advanced Resistive Exercise Device, Multi-modal Exercise Device, flywheel exercise, and aerobic exercise on a mounted treadmill and/or a cycle ergometer with vibration isolation system, have been assessed to combat the functional and mechanical losses in muscle while astronauts are in low Earth orbit. However, a lesser-understood countermeasure to muscle atrophy during spaceflight is neuromuscular electrical muscle stimulation (NMES). Although utilization in spaceflight is limited, ground-based research on NMES in diseased or injured populations demonstrates its effectiveness as a promoter of muscle anabolism and growth. The previous literature has suggested the use of electrical muscle stimulation as a low-effort modality of exercise for astronauts, which could effectively enhance astronaut health and contribute to mission success. The efficacy and mechanisms of action of using NMES to attenuate atrophy in astronauts will be discussed in this review.

## Full-text entities

- **Genes:** Gsk3b (glycogen synthase kinase 3 beta) [NCBI Gene 84027], RHOA (ras homolog family member A) [NCBI Gene 387] {aka ARH12, ARHA, EDFAOB, RHO12, RHOH12}, Eif4ebp1 (eukaryotic translation initiation factor 4E binding protein 1) [NCBI Gene 116636] {aka PHAS-I}, Des (desmin) [NCBI Gene 64362], Eif2b4 (eukaryotic translation initiation factor 2B subunit delta) [NCBI Gene 117019] {aka Eif2b}, CS (citrate synthase) [NCBI Gene 1431], PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, Ctsf (cathepsin F) [NCBI Gene 361704], Pten (phosphatase and tensin homolog) [NCBI Gene 50557] {aka MMAC1, Mmac, TEP1}, Pax7 (paired box 7) [NCBI Gene 500574] {aka RGD1564360}, Ctsb (cathepsin B) [NCBI Gene 64529], Pik3cg (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma) [NCBI Gene 298947] {aka Pi3k}, Ttn (titin) [NCBI Gene 84015] {aka connectin}, Ctss (cathepsin S) [NCBI Gene 50654], Fbxo32 (F-box protein 32) [NCBI Gene 171043] {aka Atrogin1, MAFbx}, Irs1 (insulin receptor substrate 1) [NCBI Gene 25467] {aka IRS1IRM}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}, Pax3 (paired box 3) [NCBI Gene 114502], Rps6kb1 (ribosomal protein S6 kinase B1) [NCBI Gene 83840] {aka p70 S6K-alpha}, Rps6 (ribosomal protein S6) [NCBI Gene 29304], SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, Eif4e (eukaryotic translation initiation factor 4E) [NCBI Gene 117045], Myog (myogenin) [NCBI Gene 29148], PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, Mir486 (microRNA 486) [NCBI Gene 104796156] {aka rno-mir-486}, Mir1 (microRNA 1) [NCBI Gene 100314077] {aka rno-mir-1}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, Trim63 (tripartite motif containing 63) [NCBI Gene 140939] {aka Murf, Murf1, Rnf28}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], Myf5 (myogenic factor 5) [NCBI Gene 299766], Myod1 (myogenic differentiation 1) [NCBI Gene 337868], RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 6198] {aka PS6K, S6K, S6K-beta-1, S6K1, STK14A, p70 S6KA}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, Ctse (cathepsin E) [NCBI Gene 25424] {aka CEA, CEB, Ctsea}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, Foxo1 (forkhead box O1) [NCBI Gene 84482] {aka Fkhr, Foxo1a}
- **Diseases:** fractured tibia (MESH:C535563), loss in muscle mass (MESH:C536030), hypoxia (MESH:D000860), caloric deficits (MESH:D009461), spinal (MESH:D013122), paraplegia (MESH:D010264), FES (MESH:D004556), spinal cord injuries (MESH:D013119), MD (MESH:C535955), fatigue (MESH:D005221), COPD (MESH:D029424), hypercapnia (MESH:D006935), motor neuron damage (MESH:D016472), limb girdle muscular dystrophy (MESH:D049288), atrophic (MESH:D020966), atrophy (MESH:D001284), Cancer (MESH:D009369), pain (MESH:D010146), involuntary muscle contractions (MESH:C536214), MPS (MESH:D019042), injury (MESH:D014947), Muscle Atrophy (MESH:D009133), sarcopenia (MESH:D055948), LDS (MESH:D000094024), muscle tetany and (MESH:D013746), CTS (MESH:D002349), muscular dystrophy (MESH:D009136), deficits in muscle functionality (MESH:D009135), DOMS (MESH:D063806), muscle degeneration (MESH:D009410), resorption (MESH:D014091), musculoskeletal injury (MESH:D009140), MPD (MESH:D055959), bone loss (MESH:D001847), insulin resistance (MESH:D007333), cardiovascular (MESH:D002318), hypertrophy (MESH:D006984), muscle hypertrophy (MESH:C536106)
- **Chemicals:** nitrogen (MESH:D009584), ROS (MESH:D017382), LPS (MESH:D008070), ATP (MESH:D000255), phosphocreatine (MESH:D010725), amino acid (MESH:D000596), Ca2+ (-)
- **Species:** Bos taurus (bovine, species) [taxon 9913], Rodentia (rodent, order) [taxon 9989], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941397/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941397/full.md

## References

168 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941397/full.md

---
Source: https://tomesphere.com/paper/PMC12941397